Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
19 Leser
Artikel bewerten:
(0)

Dr. David B. Agus to Present Keynote Address on the End of Illness at Accelerate2014

SAN DIEGO, March 27, 2014 /PRNewswire/ --Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software and solutions, today announced that David B. Agus, MD, one of the world's leading cancer doctors, researchers, medical futurists and technology innovators, will present the keynote address at the Accelrys user conference, Accelerate2014, which is being held from May 19-23 at the Grand Hyatt Washington, D.C.

Accelerate2014 is an exclusive five-day event designed specifically for Accelrys customers and partners with an interest in improving the efficiency, productivity and business impact of laboratory operations.

In his presentation entitled "The End of Illness," Dr. Agus will offer insights into powerful new technologies that promise to transform medicine. With a blend of storytelling, landmark research and provocative ideas, he will provide an eye-opening perspective not only on how individuals need to care for themselves but also on how scientists must develop the next generation of treatments and cures.

Dr. Agus is professor of medicine and engineering at the Keck School of Medicine of the University of Southern California (USC) and the USC Viterbi School of Engineering and heads the USC Westside Cancer Center and the USC Center for Applied Molecular Medicine. His honors and awards include the American Cancer Society Physician Research Award, a Clinical Scholar Award from the Sloan-Kettering Institute and the 2009 Geoffrey Beene Foundation's Rock Stars of Science Award. His book, "The End of Illness," was a New York Times No. 1 best seller and international best seller. His new book, New York Times best-selling "A Short Guide to a Long Life," was published by Simon & Schuster in January 2014.

Accelerate2014, the global user conference for Accelrys, offers attendees a unique forum for discussing industry trends and best practices with colleagues, keynote speakers and Accelrys executives while benefiting from expert user presentations, product demonstrations and workshops.

The conference will be opened by Max Carnecchia, President and CEO of Accelrys, Inc. and Bernard Charles, CEO of Dassault Systemes. They will set the stage for the future direction of Scientific Innovation Lifecycle Management.

The Accelerate2014 keynote sessions will highlight "the science-driven enterprise of the future" and the "laboratory of the future" with special attention to Cloud-based solutions created for global innovation networks and new modular laboratory applications supporting mobile and other Internet-connected devices that will redefine work in the laboratory. Presentations by customers and Accelrys scientific and product experts will focus on Scientific Innovation Lifecycle Management solutions for life sciences, chemicals, consumer packaged goods, food and beverages, oil and gas and other science-driven industries.

Accelerate2014 Platinum Technology Partners Microsoft and Intel will also play an important role at the global user event. Scientific Innovation Lifecycle Management solutions leveraging Microsoft technologies like Windows 8, mobility and the Windows Azure cloud platform deliver a wide range of compelling capabilities to customers. Leveraging Intel's leading processor technologies improves performance, scalability and reliability, setting the stage for new levels of enterprise intelligence.

For more information about Accelerate2014 or to register for the event, visit the event page at the Accelrys website.

About Accelrys, Inc.
Accelrys (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific foundation optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, QA/QC and manufacturing phases of product development. Accelrys offers capabilities in scientific data management, modelling and simulation, research informatics, laboratory informatics, enterprise quality management, environmental health & safety and operations intelligence for customers in science-driven industries. Using Accelrys technology, scientific innovators can access, organize, analyse and share data in unprecedented ways across the research, laboratory and manufacturing continuum, ultimately enhancing innovation, improving productivity and compliance, reducing costs and accelerating product development from research to manufacturing.

Accelrys solutions are used by more than 2,000 customers in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, CA, Accelrys employs approximately 225 full-time Ph.D. scientists. For more information about Accelrys, visit www.accelrys.com.

Accelrys, Inc. Logo.

Photo - http://photos.prnewswire.com/prnh/20140327/MM92761
Logo- http://photos.prnewswire.com/prnh/20120416/MM88629LOGO

SOURCE Accelrys, Inc.

© 2014 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.